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Abstract. – BACKGROUND: Risk factors for
suicide are at least partially heritable and func-
tional polymorphisms of targeted genes have
been suggested to be implicated in the pathogen-
esis of this phenomenon. However, other studies
examining the association between specific gene
variants and suicide revealed inconsistent find-
ings. We aims to evaluate the possible associa-
tion between MAO-A3, CYP1A2*1F and GNB3
gene variants, hopelessness and suicidal risk in a
sample of subjects with chronic migraine and af-
fective temperamental dysregulation. 
METHODS: 56 women were genotyped for
MAO-A3, CYP1A2*1F and GNB3 gene variants.
Participants were also assessed using Beck
Hopelessness Scale (BHS), the Temperament
Evaluation of the Memphis, Pisa, Paris and San
Diego-Autoquestionnaire (TEMPS-A), and the
Suicidal History Self-Rating Screening Scale
(SHSS). 
RESULTS: Patients with higher total scores on
affective dysregulated temperaments are more
likely to have higher BHS (11.27±5.54 vs.
5.73±3.81; t19.20 = -3.57; p < 0.01) and higher
SHSS total scores (4.79±3.31 vs. 1.05±2.31; t17.74
= –3.90; p < 0.001) than those with lower total
scores. 67% of patients in the dysregulated group
has BHS total scores >= 9 indicating high levels of
hopelessness. No association was found between
MAO-A3, CYP1A2*1F and GNB3 gene variants and
suicidal risk as assessed by BHS and SHSS.
CONCLUSIONS: This study did not sustain the
association between MAO-A3, CYP1A2*1F and
GNB3 gene variants and increased suicidal risk
in patients with chronic migraine and affective
temperamental dysregulation. Further studies in-
vestigating the gene-environment interaction or
focusing on other genetic risk factors involved
in suicidal behaviour are needed.
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Introduction
Suicidal behaviour is a major cause of death
and morbidity worldwide. Approximately 1 mil-
lion people died by suicide in the year 2000 and
for every completed suicide, there are at least be-
tween 10 and 40 attempted suicides1,2. A strong
bidirectional association has been suggested be-
tween psychiatric disorders, migraine and sui-
cide, presumably including common neuropathic
mechanisms. However, this relationship has often
been clinically discussed rather than systemati-
cally studied3,4. Risk factors for suicidal behav-
iour are suggested to be at least partially herita-
ble (about 40-50%)5, including genetic variants
that have been implicated in the pathogenesis of
this complex phenomenon. A recent systemic re-
view of suicide6 has suggested that additive ge-
netic factors contribute significantly to suicidal
behaviour and are largely independent of the in-
heritance of psychiatric disorder. Genetic factors
presumably affect suicide risk but the mechanism
and magnitude of the genetic contribution is still
poor understood7.
Dysfunctions in monoamine neurotransmis-
sion have been demonstrated to be associated
with suicidal behaviour. Although some studies
investigated the possible association between
MAO-A gene variant and suicide, the exact rela-
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appears to have increased activity. To our knowl-
edge, no studies exist in literature about the possi-
ble association between MAO-A, CYP1A2,
GNB3 gene variants, hopelessness, affective tem-
peraments and suicidal risk. Therefore, we aimed
to evaluate the relationship between MAO-A3,
CYP1A2*1F and GNB3 gene variants, hopeless-
ness and suicidal risk in a sample of subjects with
chronic migraine and affective temperamental
dysregulation.
Methods
Participants
Participants are 56 women with chronic mi-
graine15 followed as outpatients at Sant’Andrea
Hospital of Rome, between October 2010 and
November 2011. The mean age is 50.75 (years),
SD = 10.96 (range: 30-74 years). None of these
patients had previous diagnoses of psychiatric
disorders. Exclusion criteria were the presence of
any condition affecting the ability to complete the
assessment. To assess eligibility, patients were
evaluated by a clinician who judged their ability
to complete psychometric measures (see below),
educational level (at least five years of primary
education) and whether they had any severe med-
ical condition (information kept in the medical
record) that would impair their ability to complete
the psychometric measures. Clinical and socio-
demographic data are summarized in Table II.
Each participant provided a written informed con-
sent. The study protocol received ethics approval
from the local Research Ethics Review Board.
Women were approached during medical visits by
a medical doctor and informed that the present
study was part of a research activity designed to
gather information that would be helpful in ame-
liorating the care. Patients receiving information
about the purpose of the study were subsequently
approached by two other medical doctors who ex-
plained and administered psychometric instru-
ments. Psychometric instruments were filled out
anonymously. One-hundred and ninety-three pa-
tients were initially screened for eligibility of
which 76 were considered eligible. All patients
were Italian native speakers. Of the initial 193 pa-
tients, 117 were excluded for the following rea-
sons: 17 did not gave their informed consent to
take part in the study, for 80 patients it was not
possible to perform. Those patients who refused
to take part to the study did not differ in terms of
age or socio-demographic characteristics from
tionship between MAO-A activity and suicide
has far to be known. The MAO-A gene is located
on the short arm of the X chromosome (Xp11).
This gene has a functional polymorphism associ-
ated with transcriptional activity in which there is
a variable number tandem repeat (VNTR) in the
upstream region (MAO-A-uVNTR). However,
whether MAO-A functional polymorphism is im-
plicated in determining suicidal behaviour is still
a matter of debate. Also, another large group of
genes with the relative gene variants have been
investigated: P450 (CYP450) family of genes.
CYPs are involved in the metabolism and elimi-
nation of approximately 5-10% of many com-
monly prescribed drugs including psychotropic
medications. CYP2D6 metabolizes at least 30%
of the commonly prescribed drugs whereas the
rest is accounted by other subunits such as
CYP1A2, CYP2C9, CYP2C19 and CYP2E18. In
humans, CYP1A2 enzyme is encoded by the
CYP1A2 gene. Overall, 12 single-nucleotide
polymorphisms in CYP1A2 have been identified
of which only CYP1A2*1C (G >A) and
CYP1A2*1F (C >A) have been demonstrated to
be of functional significance9,10. CYP1A2*1C
functional polymorphism results in a significant-
ly reduced induction of CYP1A2 gene whereas
CYP1A2*1F (C >A), an intronic polymorphism
identified approximately in one out of eight
healthy volunteers10. Subjects who were homozy-
gous for A allele resulted more likely (1.6-fold)
to have an higher metabolic activity compared
with the other genotypes in this category. Detect-
ing genetic variations in drug-metabolizing en-
zymes may be useful in recognizing individuals
who may more frequently experience adverse
drug reactions with conventional doses of certain
medications. Although a considerable number of
association studies on other candidate genes have
been reported in different populations, no study
in literature has actually, to our knowledge, ex-
tensively investigated the possible association be-
tween CYP1A2 polymorphisms and suicidal be-
haviour.
Also, heterotrimeric guanine nucleotide-bind-
ing proteins genes (commonly known as G pro-
teins) and integrating signals between receptors
and effector proteins have been investigated. Sub-
unit beta-3 is a protein that in humans is encoded
by the GNB3 gene. A single-nucleotide polymor-
phism (C825T) in this gene has been associated
with essential hypertension and obesity11-14. This
polymorphism has been also associated with the
occurrence of the splice variant GNB3-s which
Mg2+
Forward primer Reverse primer Sequencing primer concentration
SNPs (5'–3') (5'–3') (5'–3') (mM)
CYP1A2*1C CTTCTTGGATGCTTATGA aTGTAATTCCAGCTACTCG ACCGCAACCTCCGCC 1
CYP1A2*1F aAGTGGAAACTGAGATGAT ATACCAGAAAGACTAAGC CTACCATGCGTCCTG 1
CYP3A4*1B GGGATGAATTTCAAGTAT aGGGTTCTTATCAGAAACT CAGCCATAGAGACAAGG 1
GNB3 C825T ACGAGAGCATCATCTG aATGGAGTCCCAGACAT ATCTGCGGCATCACG 1.5
Table I. Primers and Mg2+ concentrations for PCR amplification and pyrosequencing.
aBiotin molecule attached.
those who participated. Of the 76 patients who
accepted to participate in the study, twenty sub-
jects were excluded because it was not possible to
administer psychometric instruments (those pa-
tients were not able to complete psychometric in-
struments and although stating the intent to par-
ticipate in the study, they dropped out from both
treatment and medical visits) (an eligibility rate of
86.8%). Finally, 56 patients were considered and
included in the present study.
Genetic Analysis
We studied the following DNA polymor-
phisms: an untranslated variable number of tan-
dem repeats (uVNTR) of 30 basepairs located
about 1.1 kb upstream of the ATG initiation
codon of MAO-A gene; a A C substitution and at
position –163 and a G A transition at position
−3860 in the 50 noncoding region of the CYP1A2
gene, indicated as *1F allele (rs762551) and *1C
allele (rs2069514), respectively; an A G transition
at position −392 in the promoter region of
CYP3A4 gene, indicated as *1B allele
(rs2740574) and a C T transition at nucleotide
825 (rs5443) in the coding sequence of G protein
b3 subunit (GNB3) gene which produces a trun-
cated form of the protein. Genomic DNA was iso-
lated from peripheral blood using the X-tractor
Gene system (Corbett Life Science, Sidney, Aus-
tralia). The MAO-A promoter region polymor-
phism was genotyped on the basis of previously
described method16. Identification of the ampli-
fied fragments size was performed by microchan-
nel electrophoresis on chip, using the Agilent
2100 Bioanalyzer system (Agilent Technologies,
Santa Clara, CA, USA). All the single nucleotide
polymorphisms were genotyped by pyrosequenc-
ing technology (Pyrosequencer PyroMark ID sys-
tem, Biotage AB and Biosystems, Uppsala, Swe-
den). Forward, reverse and sequencing primers
were obtained by PSQ Assay Design software
(Biotage AB and Biosystems, Uppsala, Sweden).
PCR primer pairs and sequencing primer for each
SNP are reported in Table I.
Briefly, regions covering the SNP of interest
were amplified as follows: after initial denatura-
tion (95°C, 10 min), a thermal cycler protocol
(35 cycles) was employed cycling 20 s at 95°C,
20 s at 48°C, followed by 30 s extension at 72°C;
a final extension of 5 min at 72°C was added. All
polymerase chain reactions (PCR) reactions were
performed in a final volume of 50 μl containing
40 ng of genomic DNA, 10 pmol of each primer,
0.2 mL dNTPs (deoxynucleotide triphosphatase),
the appropriate concentration of MgCl2 (Table I),
PCR buffer and 1 U of Taq DNA polymerase
(Takara Bio Inc., Otsu, Japan). Single-stranded
DNA was isolated from the PCR reaction using
the Pyrosequencing Vacuum Prep Workstation
(Biotage, Uppsala, Sweden) and Streptavidin
Sepharose TM High Performance beads (Amer-
sham Biosciences, Uppsala, Sweden) that bind to
the biotinylated primer. After washing in 70%
ethanol, incubation in denaturing buffer and
flushing with wash buffer, the beads were then
released into a 96-well plate containing anneal-
ing buffer and the specific sequencing primer.
Annealing was performed at 80°C for 2 min fol-
lowed by cooling at room temperature. Then re-
altime sequencing was performed.
Measures
Participants completed a sociodemographic in-
terview at intake, the Beck Hopelessness Scale
(BHS)17; the Temperament Evaluation of the
Memphis, Pisa, Paris and San Diego-Autoques-
tionnaire (TEMPS-A)18; and the Suicidal History
Self-Rating Screening Scale (SHSS)19.
SHSS
Respondents were administered the SHSS, a
12-item (Yes/No) questionnaire developed by the
1391
Gene variants in subjects with chronic migraine and affective temperamental dysregulation
Participants Mean/SD Frequency/percentage
Age (years) 50.75 (10.96)
Psychiatric diagnosis 0 (0)
Comorbidity with chronic migraine 
− Migraine with sensory aura 23 (41.1)
− Migraine without sensory aura 1 (1.8)
− Migraine with sensory aura tension-type headache) 11 (19.6)
− Migraine without sensory aura (tension-type headache) 9 (16.1)
Duration of migraine attacks 24.9 (7.5)
Illness duration (years) 26.8 (7.9)
Alcohol abuse 26 (46.4)
Smoking 15 (26.8)
Cigarettes (number) 10.7 
Medications
− Triptans 47 (83.9)
− FANS 17 (30.3)
− Phenothiazines 6 (10.7)
− Alcaloids 8 (14.3)
Medications abuse 5 (8.9)
Table II. Clinical and socio-demographic data about the sample.
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hyperthymic (H), irritable (I), and anxious (A)
subscales18. The TEMPS-A has been validated in
Italian populations22.
Analysis
To reveal temperamental groupings (or clusters)
within the data set, the Authors used a Two Step
Cluster Analysis procedure. This procedure can
handle categorical and continuous variables, using
a likelihood distance measure that assumes that
the variables in the model are independent. Empir-
ical internal testing indicates that the procedure is
fairly robust to violations of both the assumption
of independence and distribution type. The two
steps of the Two Step Cluster Analysis procedure’s
algorithm can be summarized as follows (1). The
procedure begins with the construction of a Clus-
ter Features (CF) tree. The tree begins by placing
the first case at the root of the tree in a leaf node
that contains data on the variables of the case.
Each successive case is then added to an existing
node or forms a new node, based upon its similari-
ty to existing nodes and using the distance mea-
sure as the similarity criterion. A node that con-
tains multiple cases contains a summary of infor-
mation about those cases. Thus, the CF tree pro-
vides a capsule summary of the data file. (2) The
leaf nodes of the CF tree are then grouped using
an agglomerative clustering algorithm. The ag-
glomerative clustering can be used to produce a
range of solutions. To determine which number of
clusters is ‘‘best’’, each of these cluster solutions
is compared using Schwarz’s Bayesian Criterion
Authors to obtain information about previous
suicidal ideation, planning, or attempts, both in
the previous year and lifetime. It consists of two
parts: the first part explores suicidal risk in the
past twelve months, while part two explores life-
time suicidal risk. The SHSS scores range be-
tween 0-12. The SHSS had a Cronbach’s alpha
(α) reliability of 0.75 for Part I and 0.80 for Part
II, for 851 undergraduate students and an inter-
item mean correlation of 0.35 (Part 1: 0.31; Part
2: 0.41).
BHS
The BHS is a 20-item scale for measuring neg-
ative attitudes about the future. Beck originally
developed this scale in order to predict who
would commit suicide. Responding to the 20 true
or false items on the BHS, individuals can either
endorse a pessimistic statement or deny an opti-
mistic statement. Scores range between 0-20,
with higher scores indicating greater hopeless-
ness. Research consistently supports a positive
relationship between BHS scores and measures
of depression, suicidal intent, and current suici-
dal risk20. The BHS may, therefore, be used as a
proxy indicator of suicide potential. Studies on
the Italian population have been carried out and
successfully validated the scale21,22.
TEMPS-A
The TEMPS-A is a self-reportmeasure of af-
fective temperaments that define the bipolar
spectrum, with depressive (D), cyclothymic (C),
Enzyme Genotypic variants Frequency Percentage
MAO-A 3R/3R 5 8.9
3R/4R 13 23.2
4R/4R 15 26.8
4R/5R 9 16.1
5R/5R 11 19.6
Minor alleles 4 5.4
CYP 1A2*F 1F/1A 14 25
1A/1A 4 7.1
1F/1F 38 67.9
GNB3 TC 28 50
CC 23 41.1
TT 5 8.9
Table III. Genotypic frequencies and percentages of MAOA u-VNTR polymorphism, A163C CYP1A2*1F, C825T GNB3. 
Patients with low Patients with high 
levels of dysregulated levels of dysregulated
temperaments temperaments Test p <
Age (years) 51.58 ± 11.40 47.73 ± 9.01 t49 = 1.03 0.31
CYP 1A2 *F 1F/1A variant 12.2% 33.3% 0.08
GNB3 TC, TT variants 39.0% 60.0% 0.14
MAO-A 3R variant 43.5% 80.0% 0.06
BHS ≥ 9 15.0% 66.7% – –
BHS 5.73 ± 3.81 11.27 ± 5.54 t19,20 = -3.57 0.01
SHSS 1.05 ± 2.31 4.79 ± 3.31 t17,74 = -3.90 0.001
TEMP-A DEP 0.36 ± 0.14 0.72 ± 0.14 t54 = -8.53 0.001
TEMP-A CYC 0.31 ± 0.18 0.66 ± 0.12 t38,35 = -8.50 0.001
TEMP-A HYP 0.51 ± 0.18 0.37 ± 0.26 t19,02 = 1.90 0.07
TEMP-A IRR 0.16 ± 0.09 0.39 ± 0.14 t54 = -7.45 0.001
TEMP-A ANX 0.41 ± 0.16 0.74 ± 0.12 t54 = -7.08 0.001
Table IV. Differences between patients with high levels of dysregulated temperaments and patients with low levels of dysregu-
lated temperaments.
(BIC) or the Akaike Information Criterion (AIC)
as the clustering criterion. For the analysis, the
procedure was allowed to automatically determine
the number of clusters, and the Authors selected
log-likelihood distance measure and the BIC as
the clustering criteria.
Comparisons between clusters were performer
using t-tests and e One-way Fisher exact tests for
tables of contingency 2 × 2. If not otherwise indi-
cated, statistical tests are two tailed with p < 0.05.
All analyses were performed with SPSS 13.0 statis-
tical package (SPSS Inc., Chicago, IL, USA).
Results
Table III reported the genotypic frequencies
and percentages of MAO-A u-VNTR polymor-
phism, A163C CYP1A2*1F, C825T GNB3. 
The two cluster analysis indicates that partici-
pants may be clustered into two groups based on
their scores at the TEMPS-A. The first group in-
cludes 41 patients (73% of the total sample) where-
as the second group includes 15 patients (27% of
the total sample). The first group is characterized
by lower total scores in the depressive, ci-
clothymic, irritable and anxious subscales com-
pared to the second group (for more datails, see
Table IV). Therefore, the second group may be
considered as a group of patients with a high dys-
regulated affective temperament component. Pa-
tients with higher total scores on affective dysregu-
lated temperaments (compared to patients with
lower total scores) are more likely to have higher
BHS total scores (11.27±5.54 vs 5.73±3.81; t19,20 =
-3.57; p < 0.01) and higher SHSS total scores
(4.79±3.31 vs 1.05±2.31; t17,74 = –3.90; p < 0.001).
Approximately 67% of patients included in the
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dysregulated group has BHS total scores ≥ 9 indi-
cating high levels of hopelessness. The coexisting
elevated total scores at the BHS and SHSS indicate
an high suicidal risk.
The two groups are not different for any other
variable. Approximately 80% of patients with
high dysregulated temperament has a MAO-A3
variant vs. 44% of patients included in the group
with low dysregulated temperaments (this differ-
ence is not statistically significant, p = 0.06).
Similarly, approximately 60% of patients in-
cluded in the group with high dysregulated tem-
perament has a GNB3 common variant vs. 39%
of patients with low scores in the dysregulated
temperament (difference not statistically signifi-
cant, p = 0.06). The two groups are not different
for the percentage of therapeutic success
(44.00±33.62 vs. 58.21±30.07; t31 = 0.96; p =
0.35), although patients with high dysregulated
temperament have a lower percentage of thera-
peutic success compared to those with a lower
dysregulated temperament.
Discussion
This is, to our knowledge, the first study inves-
tigating the role of MAO-A, CYP1A2, GNB3
functional polymorphisms, hopelessness and sui-
cidal risk in a sample of patients with chronic mi-
graine and affective temperamental dysregulation.
The most relevant finding which was found
was that patients with higher total scores on af-
fective dysregulated temperamental component
are more likely to have higher BHS total scores
and higher SHSS total scores when compared to
patients with lower total scores. Specifically, ap-
proximately 67% of patients included in the dys-
regulated group has BHS total scores ≥ 9. Our
previous studies replicated this finding23-26. Our
reports showed that affective temperaments could
be a useful tool in screening and identifying
those who are at higher risk of suicidal behav-
iour. Also, temperaments appear as important
predictors of both suicide risk and psychopathol-
ogy and may be used in clinical practice for bet-
ter delivery of appropriate care.
However, no association was found between
MAO-A, CYP1A2, GNB3 functional polymor-
phisms, hopelessness and suicidal risk as as-
sessed by both BHS and SHSS.
This last finding is consistent with some stud-
ies suggesting that there is no association be-
tween MAO-A functional polymorphisms and
suicide attempts in subjects with bipolar
disorder27,28, major affective disorder29, schizo-
phrenia30, heroin dependence31 or psychiatric dis-
orders32. Similarly, a lack of association between
some functional polymorphisms of targeted
genes and completed suicide had also been re-
ported33. 
However, a number of contributions had indeed
suggested the existence of a significant association
between specific gene variants of targeted genes
and suicide. It has been suggested that MAO-A
functional polymorphism of the promoter region
resulting in a modification of the activity of
monoamine transmission in the central nervous
system may be associated with behavioural disor-
ders. Sabol et al34 showed that the MAO-A gene
with functional polymorphism that contains 3.5 or
4 repeats was transcribed 2-10 times more effi-
ciently than polymorphism with 2, 3, or 5 repeats.
Subjects having MAO-A 3.5R and 4R alleles
(high enzymatic activity) showed higher impulsiv-
ity/aggressiveness as well as higher suicidal risk
and depression than those with MAO-3R and 5R
alleles (low enzymatic activity). 
Also, several single nucleotide polymorphisms
in specific genes involved in metabolism and tar-
get mechanisms of triptans determining different
responses to triptans administration have been
described35,36. In a first study aimed at detecting
connections between genotypes and response to
triptans administration, a significant association
was found in 104 chronic migraine between
MAOA-4R allele, CYP1A2*1F variant (reduced
metabolic activity) and lower response to
triptans35. Also, in another sample including 150
patients with chronic migraine a significant asso-
ciation was found between MAOA-uVNTR poly-
morphism and the grade of response to triptan
administration36.
Sabol et al34 suggested that 3R and 4R alleles
are the most common alleles among different
ethnic populations. In our sample, 15 subjects
(26.8%) has been identified as having MAO-A
4R/4R genotypic variant, 13 (23,2%) MAO-A
3R/4R genotypic variant, 11 (19,6%) MAO-A
5R/5R genotypic variant, 9 (16,1%) MAO-A
4R/5R genotypic variant, and 5 (8,9%) as having
MAO-A 3R/3R genotypic variant. Only four sub-
ject (5.4%) were found to have MAO-A minor
(2R/3R, 4R/6R and 5R/6R) genotypic variants. 
Manuck et al37 reported that MAO-A 4R allele
was linked to high levels of aggressiveness and
impulsivity and low responsiveness to serotonin
confirming that MAO-A uVNTR polymorphism
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was one of the most important serotonin-related
single nucleotide polymorphism able to modulate
vulnerability to suicide38. 
The association between MAO-A allele having
high enzymatic activity and depression-related
suicide in male subjects had been reported39. The
Authors suggested that the risk of suicide at-
tempts was 3.1 times greater among carriers with
high enzymatic activity compared to carriers
with low enzymatic activity. 
Some other studies40,41 reported the existence of
an association between MAO-A functional poly-
morphism and suicide attempts. Courtet et al32
suggested that MAO-A functional polymorphism
was related to only violent suicide attempts. 
Our results are also contrary to earlier studies
suggesting an association between the MAO-A
polymorphism and suicide attempt in female pa-
tients with bipolar disorder42 and in female psy-
chiatric patients with childhood trauma history41.
Other contributions have reported an association
between MAO-A 4R and suicide in depressed
males, but not in community subjects. The Au-
thors suggested that MAO-A 4R allele might af-
fect vulnerability to suicide through the mediat-
ing factor of depressive symptoms43. Also, Lung
et al43 reported that males with 4R/4R genotypic
variant were more likely (OR = 1.586) to develop
depressive symptoms when compared to males
with 3R/3R genotypic variant. It’s important to
note that they considered a sample of male pa-
tients with major depressive disorders and no co-
morbidity whereas our sample was exclusively
composed of female outpatients with major af-
fective disorders and comorbid chronic migraine.
This might be a substantial difference.
In addition, we failed to demonstrate an asso-
ciation between the CYP1A2 and GNB3 geno-
typic variants and suicidal risk as assessed by
BHS and SHSS. No previous researches exist, to
our knowledge, in literature regarding the possi-
ble association between these genotypic variants
and suicidal risk. Some studies in literature sup-
port the association between CYP1A2 genotypic
variant, treatment outcome and response to med-
ications in major depression. 
Lin et al44 suggested that that genetypic vari-
ants of the CYP1A2 region may be indicators of
treatment response to antidepressant drugs in pa-
tients with affective disorders. Similarly, Laika et
al45 reported that the presence of genetic variants
in the CYP1A2 region was associated with thera-
peutic outcome and treatment response in psychi-
atric inpatients. Other studies did not replicate
these findings. Serretti et al46 found that the in-
vestigated allelic variations of the cytochrome
P450 do not play a major role in antidepressant
response in a sample of two hundred and seven-
ty-eight patients affected by major depression.
Also, few investigations in literature sustained
the association between GNB3 gene variant and
major depression but not suicide. A C825T poly-
morphism located in exon 10 of GNB3 was first
described in 1998 and the T allele was reported
to be associated with alternative splicing and
with increased signal transduction in human
cells47. The 825T allele has been described to be
associated with hypertension, obesity, and de-
pression in several disease-association studies.
Also, it had been showed that patients with major
depressive disorder bearing the T allele had a
more severe symptomatology and a better re-
sponse to antidepressant treatment compared to
patients without the T allele48.
The present findings must be considered in the
light of the following limitations. First, these are
preliminary data that did not allow us to general-
ize the present findings and replication in inde-
pendent larger samples is needed. Most of genet-
ic studies are limited by the small sample size
that did not allow to detect the modest genetic ef-
fect in suicide liability. 
Also, additional factors may be associated
with suicide in major affective patients including
socio-demographic factors such as level of edu-
cation, age, marital status, personality character-
istics, and anxiety symptoms. Lung et al43 sug-
gested that MAO-A uVNTR variants are com-
monly associated with different psychiatric
symptoms and the genetic effect varies with gen-
der. The fact that our sample was composed of
only female outpatients may represent a selection
bias. Also, 8.9% of these patients had medication
overuse headache (MOH) that may complicate
every type of headache and should be managed
with the withdrawal of the overused drugs to-
gether with a detoxification treatment49. 
Importantly, suicide is a complex phenomenon
determined by a series of psychophysiological
processes. It has been suggested that an heritable
and state-independent characteristic that co-seg-
regates with the condition might be a candidate
trait to improve the chances of finding a relation-
ship between this complex behaviour and geno-
type50. For example, impulsivity is an important
component of suicidal behaviour and it could be
a suitable endophenotype of suicide attempts in
genetic studies51. In our report, impulsivity was
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not assessed impeding further examination of the
relationship between MAO-A gene variant and
impulsivity. 
Another important issue comes from gene-en-
vironment interaction. Considering that genotype
does not influence suicidal behaviour by itself
but can interact with other environmental factors
to cause this complex behaviour41,52, using an ob-
jective measurement of environmental factors
might help to elucidate the possible gene-envi-
ronment interaction. The lack of psychosocial as-
sessments has also prevented the exploration of
the possible interaction between gene and envi-
ronment. Overall, inaccurate diagnostic group-
ing, lack of investigation of interaction effects,
and uncontrolled potential confounding factors
might have determined inconsistent results. 
Finally, the present results do not allow defi-
nite conclusions to be drawn and future studies
are needed in order to elucidate a more compre-
hensive analysis of the effective functional link
between MAO-A, CYP1A2, GNB3 gene variants
and suicide.
Conclusions
Affective temperaments may be considered as
a reliable predictor of suicidal risk. They could
be useful tools for clinicians in identifying those
patients who are at higher risk of suicidal behav-
iour. The non-significant association which was
found between those gene variants and suicidal
risk may suggest that they contribute only par-
tially in determining suicidal behaviour; howev-
er, these results may be presumably related to the
small sample size. 
The possible effect of gene-gene interaction or
gene-environment interaction on suicidal behav-
iour or violent suicide could not be adequately
considered. Further additional studies are needed
to evaluate the psychopathology of the relation-
ship between MAO-A, CYP1A2, and GNB3
functional polymorphisms and different subtypes
of mental diseases.
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